Kardiovaskuläre Wirkungen von Diuretika

  • H. Knauf
  • G. Hasenfuss
  • H. Just
  • E. Mutschler
Conference paper

Zusammenfassung

Vor der Verordnung eines Medikamentes sollten 2 Fragen gestellt und, wenn möglich, geklärt werden:
  1. 1.

    Wie ist die Pathogenese der Erkrankung, die behandelt werden muß, d.h. welche pathologischen Veränderungen liegen dem klinischen Bild zugrunde?

     
  2. 2.

    Wie wirkt das vorgesehene Medikament und welches Wirkprofil besitzt es?

     

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Dikshit K, Vyden JK, Forrester JS, Chatterjee K, Praksha R, Swan HJC (1973) Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure. N Engl J Med 288: 1087–1090PubMedCrossRefGoogle Scholar
  2. 2.
    Johnston GD, Hiatt WR, Nies AS, Payne NA, Murphy RC, Gerber IG (1983) Factors modifying the early non diuretic vascular effect of furosemide in man. The possible role of renal prostaglandins. Circ Res 53: 630–635PubMedGoogle Scholar
  3. 3.
    Margini F, Niarchos AP (1980) Ineffectiveness of sublingual nitroglycerin in acute left ventricular failure in the presence of massive peripheral edema. Am J Cardiol 45: 841–847CrossRefGoogle Scholar
  4. 4.
    Fracnis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN (1985) Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Ann Intern Med 103: 1–6Google Scholar
  5. 5.
    Guyton AC (1965) Interstitial fluid pressure: II. Pressure-Volume Curves of interstitial space. Circ Res 16: 452–460PubMedGoogle Scholar
  6. 6.
    Brater DC (1981) Resistance to diuretics: Emphasis on pharmacological perspective. Drugs 22: 477–494PubMedCrossRefGoogle Scholar
  7. 7.
    Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P (1981) Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. Eur J Clin Pharmacol 20: 27–33PubMedCrossRefGoogle Scholar
  8. 8.
    Hasenfuß G, Holubarsch CH, Herzog CH, Knauf H, Spahn H, Mutschler, E. Just H (1986) Influence of cardiac function on the diuretic and hemodynamic effects of the loop diuretic piretanide. Clin Cardiol (im Druck)Google Scholar
  9. 9.
    Lopez-Novaa JM, Santos JC, Caramelo C, Fernandez-Munoz D, Blanchart A, Hernando L (1984) Mechanisms of the impaired diuretic and natriuretic response to a sustained and moderate saline infusion in rat with experimental cirrhosis. Hepatology 4: 419–423CrossRefGoogle Scholar
  10. 10.
    Skorecki KL, Brenner BM (1982) Body fluid homeostasis in congestive heart failure and cirrhosis with ascites. Am J Med 72: 323–338PubMedCrossRefGoogle Scholar
  11. 11.
    Ichinawa I, Pfeffer MA, Hostetter TH, Brenner BM (1984) Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res 55: 669–675Google Scholar
  12. 12.
    Heck I, Kikis D, Knauer I, Stumpe KO, Krück F (1985) Therapie der Herzinsuffizienz Schweregrad III, IV durch Hemmung des Angiotensin-Converting-Enzyms. Klin Wochenschr 63 (Suppl IV) 12Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • H. Knauf
  • G. Hasenfuss
  • H. Just
  • E. Mutschler

There are no affiliations available

Personalised recommendations